

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

47A1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07H 21/04, C12N 15/63, 15/85, 15/09, C07K 5/00, 14/00, C12P 21/00	A1	(11) International Publication Number: WO 00/55174
		(43) International Publication Date: 21 September 2000 (21.09.00)
(21) International Application Number: PCT/US00/05988 (22) International Filing Date: 8 March 2000 (08.03.00) (30) Priority Data: 60/124,270 12 March 1999 (12.03.99) US (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (71)(72) Applicant and Inventor: ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Laytonsville, MD 20882 (US). (74) Agents: WALES, Michele, M. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: HUMAN PROSTATE CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES		
(57) Abstract		
<p>This invention relates to newly identified prostate or prostate cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "prostate cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such prostate cancer antigens for detection, prevention and treatment of disorders of the prostate, particularly the presence of prostate cancer. This invention relates to the prostate cancer antigens as well as vectors, host cells, antibodies directed to prostate cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the prostate, including prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of prostate cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.</p>		

cgcttccaga ggcgcacatgca gcggctgata gagaagtaca accagccctt cgaggacacc 240
ccggtggtgc aaatggccac gctgacctac gagacgccac agggattgag aatttgggt 300
ggaagactaa taaaggaaaag aaacaaagga gagatccagg actcctccat gaagcccgcg 360
gacaggacag atggctccgt gcaagctgca gcctggggtc ctgagcttcc ctcgcaccgc 420
acagtcctgg gagccgattc aaaaagcggg gaggtcgatg ccacgtcaga ccaggaagag 480
tcagttgctt gggccttagc acctgcagtg cctcaaagcc ctttgaaaaa tgaattaaga 540
aggaaatact tgaccaagt ggatatactg ctacaagggtg cagagtattt tgagtgtgca 600
ggtaacagag ctggaaggga tgtacgtgtg actccgctgc ctccactggc ctcacctgcc 660
gtgcctgccc ccggatactg cagtcgtatc tccggaaaaga gtcctgggtga cccagcgaaa 720
ccagcttcat ctcccagaga atgggatcct ttgcatcctt cctccacaga catggcctta 780
gtacctagaa atgacagcct ctccctacaa gagaccagta gcagcagctt cttaaagcagc 840
cagccctttg aagatgatga catttgcaat gtgaccatca gtgacctgta cgcagggatg 900
ctgcactcca tgagccgggt gttgagcaca aagccatcaa gcatcatctc caccaaaacg 960
ttsatcatgc aaaactggaa ctccaggagg aggcmergat ataagagcrg gatgaacaaa 1020
acataattgca aaggagccag acgttctcag aggagctcca aggagaactt cataccctgc 1080
tctgagcctg tgaaagggac aggggcatta agagattgca agaacgtatt agatgtttct 1140
tgccgtaaga cagggtttaa attggaaaaa gcttttcttg aagtcaacag accccaaatc 1200
cataagttag atccaagttg gaaggagcgc aaagtgcac cctcgaagta ttcttccttg 1260
atttacttcg actccagtc aacatataat cttgatgagg aaaatagatt taggacatta 1320
aaatggttaa tttctcctgt aaaaatagtt tccagaccaa caatacgaca gggccatgga 1380
gagaaccgtc agagggagat tgaaaatccga tttgatcagc ttcacgcgga atattgcctg 1440
agtcccagga accagcctcg ccggatgtgc ctcccggact cctgggccat gaacatgtac 1500
agagggggtc ctgcgaagtc ctggtggcct tnaggcttaa aaacccgnaa gctgagttaa 1567
ctttcag

<210> 741

<211> 2829

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (74)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1523)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1728)

<223> n equals a,t,g, or c

<400> 741

gacgctgggg gcagaccaca tgtcagcagt ggggtgtcgt tagtaatata ttgtgggtca 60
ttgttatttt ctnttttttg tttacttgta tttcctaaat ttttctacaa tgaacttgta 120
ttaataagaa aaaaccataa aatttactgt ttttaaaaag ctgctctaag taatcagaca 180
gtcaaaagag caggaatcag ctctccagga ggctcttttg tctggggccg aggggatgag 240
ggtgggtcct gaagacgtct gagtcccttg ttacaggagg gtgttcattg tgcctcctc 300

acagctg9ga gaacagctga agcagctggt gcctgcaagc ggcctcacag tcatggatct 360
ggaagctgag ggcacgtgtt tgcgggttcag ccctttgatg accgcagcag ttttaggaac 420
tcggggagag gatgtggatc agctcgtagc ctgcatagaa agcaaactgc cagtgtgtg 480
ctgtacgtc cagttgctg aagagttcaa gcaggaagtg gaagcaacag caggtctcct 540
atatgttgat gacctaaact ggtctggaat aggggttgtc aggtatgaac atgctaata 600
tgataagagc agtttgaaat cagatcccg aagggaatac atccatgctg gactcctgaa 660
gaagttaaat gaactggaat ctgacctaac ctttaaaata ggccctgagt ataagagcat 720
gaagagctgc ctttatgtcg gcatggcgag cgacaacgtc gatgctgctg agctcgtgga 780
gaccattgag gccacagccc gggagataga ggagaactcg aggtctctg aaaacatgac 840
agaagtgtt cggaaaggca ttcagggaagc tcaagtggag ctgcagaagg caagtgaaga 900
acggcttctg gaagaggggg tgttgcggca gatccctgta gtgggctccg tgctgaattg 960
gttttctcgg gtccaggctt tacagaaggg aagaactttt aacttgacag caggtctctt 1020
ggagtccaca gaacctatat atgtctacaa agcacaaggt gcaggagtca cgctgcctcc 1080
aacgcctcgg ggcagtcgca ccaagcagag gcttccaggc cagaagcctt ttaaaaggct 1140
cctgcgaggt tcagatgctt tgagtggagc cagctcagtc agtcacattg aagacttaga 1200
aaagtgagg cgccctatcca gtgggcccga gcagatcacc ctgcaggcca gcagactga 1260
gggacaccca ggggtcccca gccctcagca caccgaccag accgaggcct tccagaaagg 1320
gggtccacac ccagaagatg accactcaca ggtagaaggc ccggagagct taagatgaga 1380
ctcattgtgt ggtttgagac tgtactgagt attgtttcag ggaagatgaa gttctattgg 1440
aaatgtgaac tgtgccacat actaatataa attactgtt ggagtcagct tgtctaactt 1500
tggcacaaat atgtgcctga aangtaggct ttctaggagg ggagtcagct tgtctaactt 1560
catgtacatg tagaaccaca tgtttgctgt cctactacga cttttcccta agttaccata 1620
aacacatttt attcacaaaa aacacttcga atttcaagt tctaccagta gcacccttgc 1680
tctttctaaa cataagccta agtatatgag gttgcccgtg gcaacttntt tggtaaaaca 1740
gcttttcatt agcactctcc aggttctctg caacacttca cagaggcgag actggctgta 1800
tcctttgctg tcggtcttta gtacgatcaa gttgcaatat acagtgggac tgctagactt 1860
gaaggagagc agtgattgtg ggattgtaaa taagagcatc agaagccctc cccagctact 1920
gctcttcgtg gagacttagt aaggactgtg tctacttgag ctgtggcaag gctgctgtct 1980
gggactgtcc tctgccacaa ggccatttct cccattatat accgtttgta aagagaaact 2040
gtaaaagtct ctcctgacca tatattttta aatactggca aagcttttaa aattggcaca 2100
caagtacaga ctgtgctcat ttctgtttag tatctgaaaa cctgatagat gctaccctta 2160
agagcttgct cttccgtgtg ctacgtagca cccacctggg taaaatctga aaacaagtac 2220
ccctttgacc tgtctcccac tgaagcttct actgccctgg cagctcgcct gggcccaact 2280
cagaaacagg agccagcaga gcaactctct acgctgatcc agccgggcac cctgcttaag 2340
tcagtagaag ctgctgggca ctgcccgttc ctacttttcc gaagtactgc gtcactttgt 2400
cgtaagtaat gggccctgtg ccttcttaat ccagcagtc aagcttttgg agacctgaaa 2460
atgggaaaat tcacactggg tttctggact gtagtattgg aagccttagt tatagtatat 2520
taagcctata attatactct gatattgatg gatttttgac atttacactt gtcaaaatgc 2580
aggggggttt ttttggtgca gatgattaaa cagtcttccc tatttggtgc gtttttatat 2640
agcagataaa atgggggagg ggtaaattat caccttcaag aaaattacat attatttgaa 2700
atatttgaa ttgttaaat ggttttgcgt aaacatttca cccttgagat attatttgaa 2760
tgttggtttc aataaagggt cttgaaattg ttaaaaaaaa aaaaaaaa aaaaaaaa 2820
aaaaaaaaa 2829

<210> 742

<211> 926

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

485 490 495
 Met Asn Met Tyr Arg Gly Gly Pro Ala Lys Ser Trp Trp Pro Xaa Gly
 500 505 510
 Leu Lys Thr Arg Lys Leu Ser
 515

 <210> 1681
 <211> 371
 <212> PRT
 <213> Homo sapiens

 <400> 1681
 Val Pro Cys Tyr Arg Arg Val Phe Ile Val Ser Ser Ser Gln Leu Gly
 1 5 10 15
 Glu Gln Leu Lys Gln Leu Val Pro Ala Ser Gly Leu Thr Val Met Asp
 20 25 30
 Leu Glu Ala Glu Gly Thr Cys Leu Arg Phe Ser Pro Leu Met Thr Ala
 35 40 45
 Ala Val Leu Gly Thr Arg Gly Glu Asp Val Asp Gln Leu Val Ala Cys
 50 55 60
 Ile Glu Ser Lys Leu Pro Val Leu Cys Cys Thr Leu Gln Leu Arg Glu
 65 70 75 80
 Glu Phe Lys Gln Glu Val Glu Ala Thr Ala Gly Leu Leu Tyr Val Asp
 85 90 95
 Asp Pro Asn Trp Ser Gly Ile Gly Val Val Arg Tyr Glu His Ala Asn
 100 105 110
 Asp Asp Lys Ser Ser Leu Lys Ser Asp Pro Glu Gly Glu Asn Ile His
 115 120 125
 Ala Gly Leu Leu Lys Lys Leu Asn Glu Leu Glu Ser Asp Leu Thr Phe
 130 135 140
 Lys Ile Gly Pro Glu Tyr Lys Ser Met Lys Ser Cys Leu Tyr Val Gly
 145 150 155 160
 Met Ala Ser Asp Asn Val Asp Ala Ala Glu Leu Val Glu Thr Ile Ala
 165 170 175
 Ala Thr Ala Arg Glu Ile Glu Glu Asn Ser Arg Leu Leu Glu Asn Met
 180 185 190

Thr Glu Val Val Arg Lys Gly Ile Gln Glu Ala Gln Val Glu Leu Gln
 195 200 205
 Lys Ala Ser Glu Glu Arg Leu Leu Glu Glu Gly Val Leu Arg Gln Ile
 210 215 220
 Pro Val Val Gly Ser Val Leu Asn Trp Phe Ser Pro Val Gln Ala Leu
 225 230 235 240
 Gln Lys Gly Arg Thr Phe Asn Leu Thr Ala Gly Ser Leu Glu Ser Thr
 245 250 255
 Glu Pro Ile Tyr Val Tyr Lys Ala Gln Gly Ala Gly Val Thr Leu Pro
 260 265 270
 Pro Thr Pro Ser Gly Ser Arg Thr Lys Gln Arg Leu Pro Gly Gln Lys
 275 280 285
 Pro Phe Lys Arg Ser Leu Arg Gly Ser Asp Ala Leu Ser Glu Thr Ser
 290 295 300
 Ser Val Ser His Ile Glu Asp Leu Glu Lys Val Glu Arg Leu Ser Ser
 305 310 315 320
 Gly Pro Glu Gln Ile Thr Leu Glu Ala Ser Ser Thr Glu Gly His Pro
 325 330 335
 Gly Ala Pro Ser Pro Gln His Thr Asp Gln Thr Glu Ala Phe Gln Lys
 340 345 350
 Gly Val Pro His Pro Glu Asp Asp His Ser Gln Val Glu Gly Pro Glu
 355 360 365
 Ser Leu Arg
 370

<210> 1682

<211> 238

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (2)

<223> xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

What Is Claimed Is :

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of :
 - (a) a polynucleotide fragment of SEQ ID NO: X or a polynucleotide fragment of the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X ;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO: Y or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X ;
 - (c) a polynucleotide encoding a polypeptide fragment of a polypeptide encoded by SEQ ID NO: X or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X ;
 - (d) a polynucleotide encoding a polypeptide domain of SEQ ID NO: Y or a polypeptide domain encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X ;
 - (e) a polynucleotide encoding a polypeptide epitope of SEQ ID NO: Y or a polypeptide epitope encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X ;
 - (f) a polynucleotide encoding a polypeptide of SEQ ID NO: Y or the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X, having biological activity;
 - (g) a polynucleotide which is a variant of SEQ ID NO: X;
 - (h) a polynucleotide which is an allelic variant of SEQ ID NO: X;
 - (i) a polynucleotide which encodes a species homologue of the SEQ ID NO: Y;
 - (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)- (i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a protein.
3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO: Y or the polypeptide encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X.
4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO: X or the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO: X.
5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of :
 - (a) a polypeptide fragment of SEQ ID NO: Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (b) a polypeptide fragment of SEQ ID NO: Y or of the sequence encoded by the cDNA included in the related cDNA clone, having biological activity;
 - (c) a polypeptide domain of SEQ ID NO: Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (d) a polypeptide epitope of SEQ ID NO: Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (e) a full length protein of SEQ ID NO: Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (f) a variant of SEQ ID NO: Y;
 - (g) an allelic variant of SEQ ID NO: Y; or
 - (h) a species homologue of the SEQ ID NO: Y.
12. The isolated polypeptide of claim 11, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the Nterminus.
13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
15. A method of making an isolated polypeptide comprising:
 - (a) cultures2 the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed ; and
 - (b) recovering said polypeptide.
16. The polypeptide produced by claim 15.
17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.
18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
 - (a) determining the presence or absence of a mutation in the polynucleotide of claim 1 ; and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
 - (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:
 - (a) contacting the polypeptide of claim 11 with a binding partner; and
 - (b) determining whether the binding partner effects an activity of the polypeptide.
21. The gene corresponding to the cDNA sequence of SEQ ID NO: Y.
22. A method of identifying an activity in a biological assay, wherein the method comprises:
 - (a) expressing SEQ ID NO: X in a cell;
 - (b) isolating the supernatant ;
 - (c) detecting an activity in a biological assay; and
 - (d) identifying the protein in the supernatant having the activity.
23. The product produced by the method of claim 20.